Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial.

Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial.

Efficacy of oral pre-exposure prophylaxis (PrEP) in prevention of HIV acquisition has been evaluated using a daily regimen. However, adherence to long term daily medication is rarely perfect. Intermittent regimen may be a feasible alternative. Preclinical studies have demonstrated effectiveness of i...

Full description

Bibliographic Details
Main Authors: Freddie M Kibengo, Eugene Ruzagira, David Katende, Agnes N Bwanika, Ubaldo Bahemuka, Jessica E Haberer, David R Bangsberg, Burc Barin, James F Rooney, David Mark, Paramesh Chetty, Patricia Fast, Anatoli Kamali, Frances H Priddy
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3784443?pdf=render

Internet

http://europepmc.org/articles/PMC3784443?pdf=render

Similar Items